Our findings with increased CD36 and CD44 gene expression during disease progression were only confirmed in the patient cohort from Kreuzinger et al. [37] when the patients were stratified for an increase in T cell infiltration from primary to recurrent tumor sample. The gene discussed is CD36; the disease is neoplasm.